Skip to main content
Feature Story

A cultured approach to ALS therapy

By Michael J. Haas, Associate Editor

A cultured approach to ALS therapy

Although dysfunctional glial cells have long been implicated in amyotrophic lateral sclerosis progression, the precise mechanisms by which they contribute to the disease have remained poorly defined. Now, Harvard University researchers have identified a specific therapeutic target on glial cells-prostaglandin D2 receptor subtype DP1-and shown that reducing its expression can modestly prolong survival in a mouse model of the disease.1

Full Article

FDA's History

Subscribe Now
Free Trial

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.